ViiV Healthcare Announces Availability of CABENUVA and VOCABRIA in Canada

Today, ViiV Healthcare Canada announced stock availability of CABENUVA and VOCABRIA across the country. CABENUVA is the first and only once-monthly, complete long-acting injectable regimen indicated for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copiesmL). It combines the integrase strand transfer inhibitor (INSTI) cabotegravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. 1 [VOCABRIA and CABENUVA PM p4A,26A]

Both CABENUVA and VOCABRIA received approval from Health Canada on March 18, 2020 . VOCABRIA, oral cabotegravir, together with Janssen Pharmaceutical Companies of Johnson & Johnson's EDURANT, oral rilpivirine, is used for the short-term treatment of HIV-1 infection in adults who are virologically stable and suppressed prior to initiating CABENUVA. 1 [VOCABRIA and CABENUVA PM p4A]

Dacia Hibbert , General Manager of ViiV Healthcare Canada, said: "We are proud to make CABENUVA and VOCABRIA available to people living with HIV. CABENUVA will give people living with HIV the option of maintaining viral suppression with 12 treatments per year."

The approval of VOCABRIA and CABENUVA was based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 participants from 16 countries, including Canada . Prior to initiating treatment with CABENUVA, oral dosing of VOCABRIA and EDURANT was administered for approximately one month to assess the tolerability of cabotegravir and rilpivirine. The studies demonstrated that CABENUVA, when injected intramuscularly in the buttocks, once a month, was effective in maintaining viral suppression throughout the 48-week study period. 1-3 [VOCABRIA and CABENUVA PM p35A,35B, 37B ,38A][Swindells 2020 p4A,5A][Orkin 2020 p4A,5A]

In both studies, the most common adverse reactions (Grades 1 to 4) observed in ≥2% of participants receiving CABENUVA were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash, and diarrhea. Over the 48-week study period, a total of 4% of participants discontinued CABENUVA due to adverse events. 1 [CABENUVA PM p.16A,16B]

Please consult the Product Monograph at www.viivhealthcare.ca for complete safety information. The Product Monograph is also available by calling 1-877-393-8448.

About HIV
At the end of 2016, there were an estimated 63,110 people living with HIV in Canada , representing a 5% increase from 2014. The HIV prevalence rate was 173 per 100,000 population with an estimated 14% of people unaware of their status. As treatments work to reduce HIV-related mortality, and new infections are outpacing the number of deaths, the number of Canadians living with HIV will likely continue to increase in the near future. 4 [PHAC 2016 p8A,9A]

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012 . The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com .

About GSK
GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.ca.gsk.com .

References:
1. ViiV Healthcare ULC. VOCABRIA and CABENUVA Product Monograph. March 18, 2020 .
2. Swindells S et al. N Engl J Med 2020;382:1112-23.
3. Orkin C et al. N Engl J Med 2020;382:1124-35.
4. Public Health Agency of Canada . Summary: Estimates of HIV Incidence, Prevalence and Canada's Progress on Meeting the 90-90-90 HIV targets, 2016. Public Health Agency of Canada , 2018. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/summary-estimates-hiv-incidence-prevalence-canadas-progress-90-90-90/pub-eng.pdf . Accessed September 16, 2020 .

SOURCE ViiV Healthcare

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded the scope of the contract to include all of Maccabi's pharmacies and additional nurses. Maccabi is the second largest Healthcare Management Organization ("HMO") in Israel, serving over 2.6 million Israelis and is renowned for its use of technology and emphasis on patient-centered care, according to Maccabi's website here.

Pursuant to the amended agreement, Seegnal will continue to deliver its patented prescription co-pilot platform for an additional six years, to September 22, 2031, while expanding the scope to nurses and pharmacists in all of Maccabi's nationwide pharmacies. Maccabi is the first in Israel and one of the first HMOs worldwide to offer an end-to-end safety coverage throughout the patient journey, allowing complete visibility to pharmacists in the pharmacies into clinician decision while prescribing patient centric medication. The expanded contract was changed from a fixed base contract to Seegnal's current SaaS based model based on Quarterly Recurring License Fees and is expected to generate additional revenue for the Corporation.

Keep reading...Show less
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc.  (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks of 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less

Latest Press Releases

Related News

×